Our mission is to provide innovative, high performance instrumentation that enable scientists and researchers to analyze ion channels, electrogenic transporters and excitable cells. Our team of scientists and engineers is committed to constant development and improvement of our products to meet the needs of our customers. Our goal is to provide best-in-class products and customer service to enable worldwide use of our instruments in academic and industrial laboratories to advance scientific discovery and drug development in the fields of safety pharmacology, toxicology and efficacy.
Port-a-Patch, Patchliner and SyncroPatch 384:
Our first patch clamp device, the Port-a-Patch (the smallest patch clamp rig in the world), was launched in 2003. Building on the success of this instrument, the Patchliner (a fully automated patch clamp platform) was launched in 2006. In 2013 we launched the SyncroPatch 384/768PE which was the first high throughput patch clamp instrument on the market with giga-seal data quality.In 2019 the SyncroPatch 384i was launched building on the succcess of the SyncroPatch 384/768PE. In 2019 we also launched the Port-a-Patch mini, making automated patch clamp even smaller and more affordable. In 2021 we were pleased to take automated patch clamp to new levels with the SyncroPatch 384, the most flexible high throughput automated patch clamp system to date.
Orbit 16 TC, Orbit mini and Vesicle Prep Pro:
The Vesicle Prep Pro for the formation of giant unilamellar vesicles has been on the market since 2006. In 2012, the Orbit 16 was launched for automated bilayer formation and parallel recordings of 16 channels. In 2014 we introduced the Orbit mini, a 4 channel system that also features temperature control. In 2021, the Orbit 16 TC was introduced as the successor of the Orbit 16, now offering temp control.
SURFE²R 96SE and SURFE²R N1:
In 2012, we acquired the SURFE2R technology for direct functional analysis of electrogenic transporter proteins. Nanion now offers the SURFE2R N1 and has recently developed and launched (2017) a high throughput platform based on this technology, the SURFE2R 96SE – the SURF Engine!
CardioExcyte 96 and FLEXcyte 96:
In 2014, we launched the CardioExcyte 96, equipped with contractility and field potential technology, to analyze iPSC-derived cardiomyocyte networks for drug safety assessment. It also enables cell monitoring for cell viability assays on a diverse range of cells types (e. g. hepatocytes) for toxicity screening. In 2019 we launched the FlexCyte 96 in collaboration with our partners, InnoVitro, for cardiac contraction force measurements.
Nanion Technologies was founded in 2002 as a spin-off from the University of Munich, Center for Nanoscience (CeNS), where Niels Fertig undertook his PhD developing planar chip substrates for patch clamp experiments on cells and lipid bilayers. That work led to the possibility for automation and parallelization of patch clamp experiments and towards the end of his PhD, Niels co-founded the company with the goal to make automated electrophysiology a readily available technology.
Nanion management team (left to right) Niels Fertig, Andrea Brüggemann and Michael George
(image copyright Ansger Pudenz Deutscher Zukunftspreis 2014)
Nanion started with just two employees, Niels Fertig and Michael George, and the management team was completed in the second year, when Andrea Brüggemann joined. All three are physicists by training and share a healthy mix of expertise in ion channel biophysics, tech development and cell based assays together with being market driven and entrepreneurial in spirit.
Over the last 19 years, Nanion has grown to a company with almost 100 employees worldwide, at the beginning offering just one product, the Port-a-Patch, which now has increased to nine product families for all aspects of ion channel research and drug discovery, safety pharmacology, bilayer measurements and transporter research.
With the introduction of the SyncroPatch 384/768PE in 2013, Nanion entered the HTS ion channel screening market and has become the preferred choice for automated electrophysiology laboratories worldwide (HTS Tech report 2015).
From left to right: Michael George (CTO), Prof. Jan Behrends (Chairman of the board), Andrea Brüggemann (CSO), Prof. Hermann Gaub (Co-founder), Niels Fertig (CEO), Prof. Jörg Kotthaus (Co-founder)
Nanion operates globally from its headquarters in Munich, Germany, and has daughter companies in the USA, China, and Japan, with distribution partners in 5 other countries. Nanion recently moved into new headquarters in Munich’s city center, with excellent laboratories and production facilities. The above photo was taken at the house-warming party and shows the management team and all co-founders.
Our team spirit, developed through jointly working on and solving challenging interdisciplinary tasks, has fueled a responsibility for the company and each other, as well as deep friendships among the team. We learned how to listen carefully to our clients and partners: Customer feedback and scientific discoveries have always been the most important source for our product development projects. For over 15 years, our scientists have worked closely together with our engineers and software developers and we continue to create new features for our existing product platforms and develop new analytical tools and instrumentation.
We are passionate about our work: We develop smart analysis tools which meet the demands and requests of our clients.